The article highlights 12 undervalued biotech stocks favored by hedge funds, focusing on companies like MEI Pharma, Ocuphire Pharma, and Voyager Therapeutics. It discusses the biotech industry's growth, driven by innovation, M&A activity, and FDA approvals, with a positive outlook for 2024 despite challenges like drug pricing and regulatory scrutiny.